Citation: | WU Wen, ZHOU Gui-xiang, SHI Chao, . Temporal profile of specific antibody against SARS-CoV-2 among infected people: a literature study[J]. Chinese Journal of Public Health, 2022, 38(6): 804-807. doi: 10.11847/zgggws1136686 |
[1] |
Word Health Organization. Coronavirus (COVID-19) data The latest data on the COVID-19 global outbreak[EB/OL]. [2021 – 06 – 13]. https://www.who.int/data#reports.
|
[2] |
Lei Q, Li Y, Hou HY, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections[J]. Allergy, 2021, 76(2): 551 – 561. doi: 10.1111/all.14622
|
[3] |
Shen L, Wang CH, Zhao JZ, et al. Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression[J]. Emerging Microbes and Infections, 2020, 9(1): 1096 – 1101. doi: 10.1080/22221751.2020.1766382
|
[4] |
Tan WT, Lu YQ, Zhang J, et al. Viral kinetics and antibody responses in patients with COVID-19[J]. medRxiv, 2020, 24(3): 20042382. doi: 10.1101/2020.03.24.20042382.
|
[5] |
Guo L, Ren LL, Yang SY, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)[J]. Clinical Infectious Diseases, 2020, 71(15): 778 – 785. doi: 10.1093/cid/ciaa310
|
[6] |
Xiang F, Wang XR, He XL, et al. Antibody detection and dynamic characteristics in patients with coronavirus disease 2019[J]. Clinical Infectious Diseases, 2020, 71(8): 1930 – 1934. doi: 10.1093/cid/ciaa461
|
[7] |
Pan YB, Li XR, Yang G, et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients[J]. Journal of Infection, 2020, 81(1): e28 – e32. doi: 10.1016/j.jinf.2020.03.051
|
[8] |
Ng DL, Goldgof GM, Shy BR, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood[J]. Nature Communications, 2020, 11(1): 4698. doi: 10.1038/s41467-020-18468-8
|
[9] |
Yu HQ, Sun BQ, Fang ZF, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients[J]. European Respiratory Journal, 2020, 56(2): 2001526. doi: 10.1183/13993003.01526-2020
|
[10] |
Lou B, Li TD, Zheng SF, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset[J]. European Respiratory Journal, 2020, 56(2): 2000763. doi: 10.1183/13993003.00763-2020
|
[11] |
Wang YQ, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity[J]. The Journal of Clinical Investigation, 2020, 130(10): 5235 – 5244. doi: 10.1172/JCI138759
|
[12] |
Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study[J]. Clinica Chimica Acta, 2020, 507: 164 – 166. doi: 10.1016/j.cca.2020.04.026
|
[13] |
Zeng WH, Ma H, Ding CC, et al. Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 35. doi: 10.1038/s41392-021-00478-7
|
[14] |
Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients[J]. Science Immunology, 2020, 5(52): eabe5511. doi: 10.1126/sciimmunol.abe5511
|
[15] |
Seow J, Graham C, Merrick B, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection[J]. medRxiv, 2020, 9(7): 20148429. doi: 10.1101/2020.07.09.20148429.
|
[16] |
Zhang XY, Lu SW, Li H, et al. Viral and antibody kinetics of COVID-19 patients with different disease severities in acute and convalescent phases: a 6-month follow-up study[J]. Virologica Sinica, 2020, 35(6): 820 – 829. doi: 10.1007/s12250-020-00329-9
|
[17] |
Wu J, Liang BY, Chen CR, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19[J]. Nature Communications, 2021, 12(1): 1813. doi: 10.1038/s41467-021-22034-1
|
[18] |
Kulkarni R, Patil HP, Palkar S, et al. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA[J]. Journal of Virological Methods, 2021, 287: 113996. doi: 10.1016/j.jviromet.2020.113996
|
[19] |
Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19[J]. The Journal of Allergy and Clinical Immunology, 2021, 147(2): 545 – 557.e9. doi: 10.1016/j.jaci.2020.10.040
|
[20] |
Caturegli G, Materi J, Howard BM, et al. Clinical validity of serum antibodies to SARS-CoV-2: a case-control study[J]. Annals of Internal Medicine, 2020, 173(8): 614 – 622. doi: 10.7326/M20-2889
|
[21] |
Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19[J]. Nature Medicine, 2020, 26(6): 845 – 848. doi: 10.1038/s41591-020-0897-1
|
[22] |
Li CS, Yu D, Wu X, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan[J]. Nature Communications, 2021, 12(1): 4144. doi: 10.1038/s41467-021-24230-5
|
[23] |
Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity[J]. Immunity, 2020, 53(5): 925 – 933.e4. doi: 10.1016/j.immuni.2020.10.004
|
[24] |
Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2[J]. Science Translational Medicine, 2021, 13(577): eabd2223. doi: 10.1126/scitranslmed.abd2223
|
[25] |
Jiang XL, Wang GL, Zhao XN, et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection[J]. Nature Communications, 2021, 12(1): 897. doi: 10.1038/s41467-021-21155-x
|
[26] |
Wu F, Wang AJ, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications[J]. medRxiv, 2020, 30(3): 20047365. doi: 10.2139/ssrn.3566211.
|
[27] |
Grzelak L, Temmam S, Planchais C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations[J]. Science Translational Medicine, 2020, 12(559): eabc3103. doi: 10.1126/scitranslmed.abc3103
|
[28] |
He ZY, Ren LL, Yang JT, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study[J]. The Lancet, 2021, 397(10279): 1075 – 1084. doi: 10.1016/S0140-6736(21)00238-5
|
[29] |
Sinderewicz E, Czelejewska W, Jezierska-Wozniak K, et al. Immune response to COVID-19: can we benefit from the SARS-CoV and MERS-CoV pandemic experience?[J]. Pathogens, 2020, 9(9): 739. doi: 10.3390/pathogens9090739
|
[30] |
Guo XQ, Guo ZM, Duan CH, et al. Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers[J]. medRxiv, 2020, 12(2): 20021386. doi: 10.1101/2020.02.12.20021386.
|
[31] |
Alshukairi AN, Zhao JC, Al-Mozaini MA, et al. Longevity of middle east respiratory syndrome coronavirus antibody responses in Humans, Saudi Arabia[J]. Emerging Infectious Diseases, 2021, 27(5): 1472 – 1476.
|
[32] |
Cao WC, Liu W, Zhang PH, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery[J]. The New England Journal of Medicine, 2007, 357(11): 1162 – 1163. doi: 10.1056/NEJMc070348
|
[33] |
Li G, Chen XJ, Xu AL. Profile of specific antibodies to the SARS-associated coronavirus[J]. The New England Journal of Medicine, 2003, 349(5): 508 – 509. doi: 10.1056/NEJM200307313490520
|
[34] |
孙永, 何军, 蔡芬, 等. 新型冠状病毒IgG/IgM抗体双重检测免疫层析方法的建立研究[J]. 合肥工业大学学报: 自然科学版, 2020, 43(5): 700 – 705.
|
[35] |
崔小平, 崔犇, 杜红心, 等. 新型冠状病毒IgM和IgG抗体检测对新冠肺炎的诊断效能评价[J]. 现代医药卫生, 2020, 36(19): 3015 – 3017. doi: 10.3969/j.issn.1009-5519.2020.19.003
|